2 results
Approved WMOCompleted
Part 1: To assess the safety and effectiveness of subcutaneous golimumab 50 mg (SC-GLM50), administered by autoinjection once monthly during 6 months, when combined with different DMARD regimens used in daily rheumatology. Part 2: In subjects who…
Approved WMOPending
Aim of this study proposal· To establish whether oral phosphorus binding is able to reduce FGF23 levels in patients with CKD stage 3.· To evaluate if a reduction of serum phosphate and FGF23 improves vascular function as measured by pulse-wave-…